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Control of colorectal cancer needs to be tailored to its etiology. Tumor promotion mechanisms in colitis-
associated colon cancer differ somewhat from the mechanisms involved in hereditary and sporadic
colorectal cancer. Unlike sporadic or inherited tumors, some experimental models show that colitis-
associated colon tumors do not require cyclooxygenase (COX) expression for progression, and non-
steroidal anti-inﬂammatory drugs (NSAIDs) which prevent sporadic or inherited colon cancer do not
prevent colitis-associated colon cancer. We report that myeloperoxidase (MPO), an ancestor of the COX
isoenzymes, is a determinant of colitis-associated colon tumors in ApcMin/þ mice. During experimentally
induced colitis, inhibition of MPO by resorcinol dampened colon tumor development. Conversely, in the
bowels of ApcMin/þ mice without colitis, resorcinol administration or ‘knockout’ of MPO gene coincided
with a slight, but discernible increase in colon tumor incidence. Acrolein, a by-product of MPO catalysis,
formed a covalent adduct with the phosphatase tensin homolog (PTEN) tumor suppressor and enhanced
the activity of the Akt kinase proto-oncogene in vitro and in vivo. Thus, MPO may be an important
determinant of diet and inﬂammation on colon cancer risk via its effect on endogenous exposure to
oxidants and acrolein. We propose a hypothetical model to explain an apparent dichotomy between
colon tumor occurrence and MPO inhibition in inﬂamed versus non-inﬂamed colons.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic ulcerative colitis is an independent risk factor for col-
orectal cancer [1,2]. Consistent with epidemiological observations
in humans, experimentally-induced colitis increases colon tumor
progession in the ApcMin/þ mouse, a model of intestinal cancer [3–
7]. While the molecular pathways of inherited, sporadic and coli-
tis-associated colon tumor progression overlap, they are not
identical [8,9]. Tumor formation in some mouse models of colitis-B.V. This is an open access article u
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-Salihi),associated colon cancer does not require cyclooxygenase (COX)
expression [10]. In a study using COX-1 and COX-2 ‘knockout’
mice, investigators concluded that the mechanism of colorectal
tumor promotion in colitis-associated cancer differs from the
mechanism of tumor promotion for hereditary and sporadic col-
orectal cancer [10]. However, the exact role of prostaglandins in
colitis associated colorectal cancer models varies with the model
[11]. Additionally, the pharmacological rationale for colon cancer
prevention with non-steroidal anti-inﬂammatory drugs (NSAIDs)
does not apply to colitis-associated tumors [12,13]. In fact, NSAIDs
aggravate inﬂammation and malignant progression in rodent
models of colitis-associated tumors [14–16], albeit with some ex-
ceptions [17]. One NSAID, 5-aminosalicylic acid, can maintain re-
mission of ulcerative colitis, which ought to prevent colitis-asso-
ciated colon cancer. However, that hypothesis is unproven despite
many attempts at validation [12,18].
Myeloperoxidase (MPO), an ancestor of COX enzymes [19],
helps gut associated lymphoid tissue defend against harmful en-
teric microbes, while tolerating harmless commensal bacteria and
dietary antigens. Because MPO activity correlates with the severity
of experimentally induced colitis [20] and its expression is annder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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colon tumor development in ApcMin/þ mice. We report that ele-
vated MPO activity in the inﬂamed bowels of ApcMin/þ mice cor-
related with greater colon tumor occurrence; inhibition of MPO
activity in inﬂamed colons of ApcMin/þ mice partly suppressed
colon tumor occurrence. Conversely, tumors were absent or rare in
non-inﬂamed colons with low, basal MPO activity in ApcMin/þ
mice. Unexpectedly, either pharmacological or genetic suppression
of basal MPO activity correlated with a small, but discernible rise
in colon tumors in ApcMin/þ without colitis. Thus, the relationship
between MPO activity and colon tumor occurrence in ApcMin/þ
mice varies with the status of inﬂammation in the gut. Our me-
chanistic experiments found that a carcinogenic by-product of
MPO catalysis, acrolein, formed a protein adduct with phosphatase
tensin homolog (PTEN) in colonocytes isolated from the inﬂamedFig. 1. Myeloperoxidase and colitis-associated colon tumors in ApcMin/þ Mice. Panel A: p
MPO activity with resorcinol in ApcMin/þ mice. Panel B: colitis-associated tumors (arro
sorcinol. Panel C: graphs of colon tumor numbers, volumes and loads in colons from Dbowel of ApcMin/þ mice. Modiﬁcation of the PTEN tumor sup-
pressor coincided with activation of the Akt kinase proto-onco-
gene, which favors cell growth and survival. Since acrolein can
originate endogenously from MPO mediated oxidation of threo-
nine or serine [22] this mechanism may contribute to complex
effects of diet on inﬂammation and colon cancer risk.2. Materials and methods
2.1. Reagents
The following were used: resorcinol, acrolein, L-threonine,
hydrogen peroxide (H2O2) and 3-methyl-2-benzothiazolinone hy-
drazone hydrochloride monohydrate (MBTH) (Sigma Aldrich, St.rotocol for induction of colitis with dextran sodium sulfate (DSS) and modulation of
ws) in representative colons from DSS-ApcMin/þ mice treated with vehicle or re-
SS-ApcMin/þ mice treated with vehicle (n¼13) or resorcinol (n¼10).
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Athens, GA); myeloperoxidase activity EnzCheks assay kits;
complete protease inhibitor mixture (Roche Molecular Biochem-
icals, Indianapolis, IN); lysis buffer A, 0.6% Igepal CA-630 in PBS
(Promega, Madison, WI); wortmannin, primary antibodies against
PTEN, Akt, phospho-(Ser473)Akt (Cell Signaling Technologies,
Danvers, MA); rabbit polyclonal antibodies to PTEN (Upstate, Lake
Placid, NY); anti-acrolein adduct antibody (Cosmo Bio Co. Ltd.,
Tokyo, Japan); horseradish peroxidase-conjugated (HRP) second-
ary antibodies and protein A/G PLUS-Agarose (Santa Cruz Bio-
technology; Santa Cruz, CA); polyvinylidene diﬂuoride (PVDF)
membranes and Western Lightning chemiluminescence reagents
(Perkin-Elmer, Waltham, MA); and dextran sodium sulfate, MW
36,000–50,000 (MP Biomedicals, Solon, OH). Lysis buffer B was
50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.2%
deoxycholic acid sodium salt, 0.1% SDS, 1 mM phenylmethylsulfo-
nyl ﬂuoride, 5 μg/ml aprotinin, 5 μg/ml leupeptin, and 5 μg/ml
pepstatin A. Authenticated HCT116 colon cancer cells and MCF-7
breast cancer cells were from ATCC (Manassas, VA).
2.2. Mice experiments and husbandry
All mice experiment protocols (Fig. 1A) were approved by the
University of Utah Institutional Animal Care and Use Committee.
Equal numbers of male and female mice were used throughout the
study. ApcMin/þ mice (C57BL/6J-ApcMin/J), and their corresponding
C57BL/6J wild type littermates were obtained from Jackson La-
boratories, Bar Harbor, ME. MPO ‘knockout’ mice
(B6.1291-Mpotm1Lus/J) procured from Jackson Laboratory were
bred on a C57BL/6J background through at least 10 generations. A
strain is considered fully congenic after ten generations of back-
crossing (N10). Transgenic mice (ApcMin/þ/MPO/) on a C57Bl/6J
background were identiﬁed by PCR ampliﬁcation of genomic DNA
isolated from mouse tails using salt precipitation. All mice, kept in
standard housing conditions, and fed 8656 Teklad sterilizable ro-
dent diet (Harlan Laboratories, Denver, CO). Mice were sacriﬁced
by CO2 asphyxiation.
2.3. DSS induced colitis
At 8 weeks of age ApcMin/þ or wild type mice were given
drinking water containing 2.5% (w/v) DSS for 7 days. The occur-
rence and severity of colitis was measured by quantifying the MPO
activity, a proxy for colitis, in the intestinal mucosa of mice [20].
Both peroxidase and chlorination activity were quantiﬁed, with
chlorination being a more speciﬁc index of MPO activity. We used
EnzCheks MPO activity assay kits, following the manufacturer's
protocol. Brieﬂy, the assay measures selective cleavage of 3′-(p-
aminophenyl) by hypochlorite (OCl) to yield ﬂuorescein. Stock
reagents include 3′-(p-aminophenyl) ﬂuorescein (5 mM in di-
methyformamide) and 5 mM H2O2 prepared fresh daily in phos-
phate-buffered saline (PBS), pH 7.2. The substrate-cofactor work-
ing solution is a combination of 20 μM 3′-(p-aminophenyl) ﬂuor-
escein and 20 μM H2O2 in PBS, pH 7.2. Experimental samples
(50 μL of tissue lysate) or MPO standards were added to 96-well
microplates suitable for measuring ﬂuorescence. MPO catalysis
was initiated by adding substrate-cofactor working solution
(50 μL) at 25 °C. Plates were covered with tin foil to protect from
ambient light. The ﬂuorescence intensity of ﬂuorescein formed by
MPO activity in each sample was measured continuously using
excitation at 485 nm and emission at 530 nm. MPO activity is
proportional to the rate of change of ﬂuorescence in the linear
portion of the curve, typically around 30 min after starting the
reaction. Reaction rates were calculated after correction using a
negative control (boiled samples plus MPO inhibitor). MPO levels
were calibrated using serially diluted (1:2) MPO standard solutionsranging from 0 to 200 ng/ml. When resorcinol was used as an
inhibitor it was added simultaneously with the substrate co-factor
solution.
2.4. Tumor studies
ApcMin/þ mice were divided into four groups. Starting at
8 weeks of age two groups of ApcMin/þ mice were treated with
2.5% (w/v) DSS for 7 days, while the remaining two groups were
given water. The MPO inhibitor resorcinol (1.25 mg/kg) or saline
vehicles (0.20 ml) were injected once daily, i.p., for the duration of
the DSS treatment. Mice were allowed to mature a further 6 weeks
before being sacriﬁced. In addition, two separate groups of
ApcMin/þ and ApcMin/þ x MPO/ double mutant mice were ma-
tured to the same age as above and sacriﬁced to compare the effect
of pharmacological inhibition of MPO by resorcinol [23] versus a
genetic ‘knockout’ of MPO in a non-colitis background.
2.5. Tissue harvesting and tumor assessment
The small intestine and colon were dissected longitudinally and
washed with ice-cold PBS. They were then ﬁxed for 4 h in 10%
formalin in PBS, and stored in 70% ethanol at 4 °C. The intestine
and colons were stained with methylene blue, and then polyps
and colon tumors were counted with the aid of a dissecting mi-
croscope. The counting studies were independently performed by
two individuals who had no knowledge of the genotype and/or
type of treatment used for each mouse. Colon tumors were pho-
tographed, the largest and smallest diameters were recorded, and
tumor volumes were calculated according to the equation (volume
(mm3)¼π/6 largest diameter smallest diameter2). Tumor load
was calculated by summing all measured tumor volumes in a
mouse.
2.6. Generation of acrolein in situ by MPO
2-Hydroxy-propenal and acrolein (2-propenal) were generated
by incubating 1.5 μg MPO (10 nM), 150 mM chloride and 200 μM
L-threonine in 1.0 ml of 0.05 M phosphate buffer, pH 7.0, at 37 °C
[22]. The reaction was initiated by the addition of 200 μM H2O2.
For some experiments incubation times were varied, MPO was
omitted, or the MPO inhibitor resorcinol (0–100 μM) was added.
Formation of 2-hydroxy-propenal and acrolein were quantiﬁed
spectrophotometrically by measuring the absorbance of their
MBTH derivative at 598 nm. The assay was calibrated with acrolein
standards. Brieﬂy, a sample of the MPO reaction mixture (200 μl)
was incubated for 20 min, 25 °C with 568 μl of sodium phosphate
buffer (5 mM, pH 7.0), 25 μl HCl (6 N), and 132 μl of MBTH
(155 mM). The derivative was then reacted with 75 μl FeCl3
(370 mM) and incubated for 10 min at 25 °C. The MBTH derivative
was stable for at least 5 h.
2.7. Cell culture
HCT116 cells were grown in modiﬁed Eagle's medium (MEM)
with 10% fetal bovine serum (FBS), 100 units of penicillin/strep-
tomycin, 2 mM L-glutamine, and 1 mM pyruvate. MCF-7 cells were
grown in MEM with 10% v/v FBS, 2 mM L-glutamine, 1.5 g/l
NaHCO3, 0.1 mM non-essential amino acids, 1 mM sodium pyr-
uvate, 0.01 mg/ml bovine insulin, and 0.01 mg/ml gentamicin.
2.8. MPO dependent modulation of PTEN–Akt signaling
HCT 116 and MCF-7 cells were grown to 80% conﬂuency;
culture media was removed and replaced with 2 ml of 0.05 M
phosphate buffer, pH 7.0, MPO, chloride and threonine as detailed
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addition to cells. Cells were exposed to the reaction products at
37 °C for intervals from 0 to 30 min. For some experiments MPO
was omitted, or resorcinol (0–100 μM) was added to modulate
MPO dependent generation of reactive aldehydes. A phosphatidyl-
inositol-3-kinase (PI3-K) inhibitor, wortmannin, was used as a
control to modulate Akt activation. Treated cells were lysed in
250 mM sucrose, 50 mM Tris pH 7.4, 5 mMMgCl2, 1 mM EGTA, 1
complete protease inhibitor, 2 mM NaF and 2 mM sodium ortho-
vanadate. Lysates from treated cells (15 mg protein) were fractio-
nated on SDS-10% PAGE and proteins were transferred to poly-
vinyldiﬂuoride membranes for immunoblot analysis of Akt and
phospho-(S473) Akt as described [24,25].
2.9. Detection of acrolein-PTEN adducts in colonocytes from in-
ﬂamed and non-inﬂamed colons of mice
After treatment of ApcMin/þ mice with either vehicle or DSS,
7resorcinol, (Fig. 1A) colons were removed. Colon crypts, and the
colonocytes within, were isolated as described [26]. Longitudinally
dissected colons were incubated in PBS containing 3 mM EDTA
and 50 μM DTT for 90 min at 4 °C. The colons were then washed
and vigorously shaken in ice-cold PBS 3–4 times to release intact
colon crypts and wash away any leukocytes. Colon crypts and their
colonocytes were enriched via centrifugation at 40g for 10 min at
4 °C, and then reconstituted in ice-cold cell lysis buffer.
Colon crypts were lysed in buffer B and their PTEN protein was
isolated by immunoprecipitation. Brieﬂy, lysates were pre-cleared
by incubation with 2 μg of mouse IgG and 20 μl of protein G PLUS
agarose at 4 °C for 30 min and centrifuged at 1000g at 4 °C for
5 min. Aliquots containing equivalent amounts of total cellular
protein were immunoprecipitated using 1 μg of mouse mono-
clonal anti-PTEN by incubation at 4 °C for 2 h. Immune complexes
were precipitated by incubation with 20 μl of protein G PLUS
agarose at 4 °C overnight and collected by centrifugation. Im-
munoprecipitates were washed four times with lysis buffer B, re-
suspended in Laemmli buffer, separated on a 10% SDS-poly-
acrylamide gel, and transferred to PVDF membranes. After block-
ing with 5% powered milk in 10 mM Tris–HCl, pH 7.5, 100 mM
NaCl, and 0.1% Tween 20, acrolein-modiﬁed PTEN was detected
with the monoclonal antibody mAb5F6 (1:5000 dilution) [27]
followed by horseradish peroxidase-conjugated mouse anti-goat
IgG (1:10,000 dilution) followed by detectionwith ECL Pluss. Blots
were stripped using buffer containing 62.5 mM Tris–HCl, pH 6.7,
100 mM 2-mercaptoethanol, 2% SDS, at 55 °C for 30 min, and re-
probed with the rabbit polyclonal antibodies to PTEN and visua-
lized with HRP-conjugated secondary antibody followed by ECL
Pluss.Table 1
MPO activity* in colon crypts from Apc Min/þ mice treated with DSS7resorcinol.
DSS control DSSþresorcinol % MPO inhibition
Day 1 53.778.1 (n¼3) 29.074.3 (n¼3) 46.078.0
Day 3 59.977.5 (n¼3) 33.172.2 (n¼3) 44.773.6
Day 6 36.878.4 (n¼6) 9.072.1 (n¼6) 75.575.7
* Mean7std. dev. (pg MPO/μg protein).2.10. Western immunoblotting
Samples were dissolved in 50 ml of Laemmli loading buffer, 0.5%
BME and heated at 95 °C for 10 min. Samples (15–30 mg protein)
were fractionated by SDS-PAGE and transferred to polyvinyldi-
ﬂuoride membranes. Membranes were blocked with 5% w/v
nonfat dry milk in tris buffered saline with Tween 20, and then
incubated for 16 h at 4 °C with primary antibodies, followed by
HRP-conjugated secondary antibody (1:5000). Antigen–antibody
complexes were detected with Western Lightning ECL reagents.
The intensity of chemiluminescent protein-antibody complexes
was quantiﬁed with a Kodak Image Station 440. Bar graphs depict
the mean7standard error from densitometric analyses of sepa-
rate experiments.2.11. Statistical analysis
Data was analyzed using the Microsoft Excel statistical package.
A two-tail homoscedastic or heteroscedastic unpaired Student's t-
test was used. A p-value of less than 0.05 was considered statis-
tically signiﬁcant.3. Results
3.1. Leukocyte MPO activity in DSS-induced colitis correlates with
colon tumor occurrence in ApcMin/þ mice
At 10–12 weeks after birth, ApcMin/þ mice fed a standard diet
and normal drinking water have intestinal polyps, but few or no
colon tumors [28]. In our experiments 42% of ApcMin/þ control
mice were free of any colon tumors and the others had only
1.3 colon tumors per mouse (range 1–3 colon tumors/mouse).
ApcMin/þ mice exposed to 2.5% w/v DSS in drinking water have
increased colon tumor occurrence [29]. In our protocol all mice
developed colon tumors, secondary to their colitis (100% in-
cidence). The colon tumor number rose 13-fold to a mean¼17.3
tumors per colon, range 3–37; with a median tumor
volume¼8.3 mm3, range 4.9–16.2 mm3 and an average tumor
load¼112.8 mm3, range 44.9–245 mm3. Leukocyte MPO activity in
the colon, a proxy for colitis [22], rose 2.5-fold in DSS-treated mice
compared to controls given normal drinking water.
Resorcinol, administered once daily (1.25 mg/kg, i.p.) for 7 days
[Fig. 1A], inhibited MPO activity by 50% on day 1 and 3, and 75%
on day 6 in ApcMin/þ mice with DSS colitis [Table 1]. On day 6,
leukocyte MPO activity in the mucosa of mice treated with DSS
plus resorcinol was comparable to basal MPO activity in the mu-
cosa from ApcMin/þ mice given normal drinking water. Corre-
sponding with its suppression of MPO activity in the inﬂamed gut,
resorcinol lessened colitis-associated colon tumor development
[Fig. 1B and C]. Resorcinol reduced incidence by 10% and tumor
multiplicity and tumor volume by 38%. Resorcinol-treated mice
had a mean tumor number¼10.7, range 0–21, and a median tumor
volume¼5.2 mm3, range 0.8–10.3 mm3. As mentioned above, the
vehicle control mice had a comparative mean tumor
number¼17.3, range 3–37, and a median tumor volume¼8.3 mm3,
range 4.9–16.2 mm3. Resorcinol also reduced tumor load by 46%.
Resorcinol-treated mice had an average tumor load¼60.7 mm3,
range 0.8–106.6 mm3; while the control mice had an average tu-
mor load¼112.8 mm3, range 44.9–245 mm3. In these same mice,
resorcinol reduced the number of polyps in the small intestine, by
20%, but this was not statistically signiﬁcant.
3.2. MPO activity in the non-inﬂamed gut of ApcMin/þ mice corre-
lates inversely with colon tumors
ApcMin/þ mice fed a standard diet and normal drinking water-
with no DSS-had few or no colon tumors [Fig. 2, upper panel].
Administration of resorcinol (1.25 mg/kg) to these mice was as-
sociated with a small but discernible increase in colon tumor in-
cidence from 58% during vehicle treatment, to 85% during
Fig. 2. Effects of resorcinol and genetic ‘knockout’ of myeloperoxidase on inherited
colon tumors in ApcMin/þ mice without DSS-colitis. Tumor numbers in colons from
ApcMin/þ mice treated with vehicle (n¼15); ApcMin/þ/MPO/ treated with vehicle
(n¼16) or ApcMin/þ mice treated with resorcinol (n¼14) administered at times and
doses shown in Fig. 1A. Incidence of tumor occurrence was 58%, 85% and 85%,
respectively.
Fig. 3. Myeloperoxidase enhances cellular Akt kinase activation via acrolein gen-
eration in vitro. Panel A. Time-course of acrolein generation via MPO-mediated
formation of threonine chloramine. Active MPO+substrate ; active
MPOþsubstrateþresorcinol ; substrate alone . Arrows indicate supple-
mental addition of MPO, threonine, or H2O2 to determine the relationship between
their consumption and acrolein production: depletion of H2O2 limited acrolein
generation. Panel B. Relative levels of acrolein generated via chemical (HOCl) versus
MPO mediated formation of threonine chloramine. These data correspond with
experiments shown in panel C. Panel C. Immunochemical analysis of phospho-
Ser473 Akt, a biomarker of cellular Akt activation in HCT 116 and MCF 7 cells ex-
posed to acrolein via MPO-mediated formation of threonine chloramine±resorcinol
and wortmannin.
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mean¼1.3 (range 0–3) in mice treated with normal drinking wa-
ter, to a mean¼2 (range 0–7) in corresponding ApcMin/þ mice
treated with resorcinol [Fig. 2, upper panel]. Exposure to resorcinol
did not alter the tumor volume or tumor load in these mice under
our protocol (not statistically different, p40.05) [Fig. 2, middle
and lower panels]. We draw attention to the fact that fewer tu-
mors occur in non-inﬂamed colons (Fig. 2), compared to inﬂamed
colons (Fig. 1).
Results in Fig. 2 imply that resorcinol may have impeded any
role that MPO has in anti-tumor host-defense processes under
basal conditions in the colon of ApcMin/þ mice. Alternatively, re-
sorcinol, or its metabolites, in ApcMin/þ mice may have been car-
cinogenic. To address this issue we examined colon tumor for-
mation in ApcMin/þ/MPO / mice fed a standard diet and normal
drinking water. In these mice genetic ‘knockout’ of the MPO gene
heightened colon tumor incidence and number to the same extent
(85%) as pharmacological suppression of MPO by resorcinol
[Fig. 2]. Like resorcinol, ‘knockout’ of the MPO gene only altered
tumor incidence and number, but not the tumor volume or tumor
load in ApcMin/þ mice in our protocol (p40.05).
3.3. Acrolein, a by-product of threonine and MPO catalysis, forms an
adduct with PTEN, thereby enhancing Akt kinase proto-oncogene
signaling
Reactive lipid-enals and -enones generated by COX or lipox-
ygenase enzymes during inﬂammation can irreversibly modify the
PTEN tumor suppressor, inactivate its inositol phosphatase activ-
ity, and thereby nullify its restraint of Akt proto-oncogene sig-
naling [24,25]. MPO can generate acrolein, a prototypical-enal
carcinogen [30], from hydroxyl-amino acids at sites of inﬂamma-
tion [22] [Fig. 3A and B]. When HCT 116 or MCF 7 cells were ex-
posed in situ to acrolein generated by MPO, threonine, hydrogen
peroxide, and chloride ions, the cells accumulated higher amounts
of phospho-Ser473Akt, an index of Akt kinase activation. The MPO
inhibitor, resorcinol, suppressed the formation of cellular
phospho-Ser473-Akt [Fig. 3C] to about the same extent as 0.5 μM
wortmannin, an inhibitor of phosphatidylinositol-3-kinase.
During DSS-induced colitis, inﬂammation may expose colono-
cytes of ApcMin/þ mice to the processes depicted in Fig. 3. Con-
sistent with this mechanistic hypothesis, colon crypts isolated
from inﬂamed bowels of ApcMin/þ mice contained PTEN protein
that was post-translationally modiﬁed by acrolein [Fig. 4A]. For-
mation of acrolein-PTEN adducts in colonocytes also correspondedwith Akt kinase activation (increased phospho-Ser473-Akt levels)
and with the MPO activity in the samples [Fig. 4B].4. Discussion
Colon tumor occurrence correlates with high MPO activity
found in DSS-inﬂamed colons of ApcMin/þ mice. MPO can generate
oxidants that cause DNA damage, and mutagenesis [30]; it can also
generate acrolein as an oxidative by-product from unsaturated
fats, serine, or threonine [31]. Acrolein–protein adducts in colon
Fig. 4. Post-translational modiﬁcation of the PTEN tumor suppressor and activation
of cellular Akt kinase activation in colonocytes isolated from ApcMin/þ mice. Panel
A. Immunoblot and bar graph of acrolein-PTEN adducts in the total PTEN content
isolated from colonocytes of ApcMin/þ mice or DSS-ApcMin/þ mice treated with
vehicle or resorcinol, respectively. The lower immunoblot depicts phospho-Ser473
Akt, a biomarker of cellular Akt activation in the same samples of colonic mucosa.
Panel B. MPO activity in the mucosa of ApcMin/þ mice or DSS-ApcMin/þ treated with
vehicle or resorcinol, respectively.
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colon tumors in humans [32]; however, little is known about the
identity of proteins that form acrolein adducts, or their role in the
etiology of colon tumor progression. In colonocytes isolated from
ApcMin/þ with inﬂamed colons we found that PTEN, a prominent
intestinal tumor suppressor, formed a protein adduct with acro-
lein. PTEN modiﬁcation coincided with Akt proto-oncogene acti-
vation in these colonocytes. Reactive nitrogen species also re-
portedly oxidize PTEN and disable its restraint of Akt kinase sig-
naling [33]. Thus, MPO metabolites or by-products may augment
colitis-associated colon tumor occurrence via genetic and en-
ergetic mechanisms [34]. Genetically, oxidants and acrolein have
mutagenic potential [30,35]. Energetically, oxidants and acrolein
enhance anabolic signaling via the PI3-kinase–PTEN–Akt kinase
axis. While speculative, this latter mechanism can account for the
increased size of colon tumors reported in the DSS-ApcMin/þ
model [3,5].
Colon tumors are absent or rare in non-inﬂamed colons of
ApcMin/þ mice with physiologically basal MPO activity. Under
these conditions, inhibition or genetic deletion of MPO coincided
with a small but discernible rise in colon tumors. Thus, there is a
dichotomy between MPO activity and colon tumor occurrence in
ApcMin/þ mice. During DSS-induced colitis, high MPO activity fa-
vors colon tumor development; inhibition of MPO during DSS-
colitis partly prevents colon tumors. However, under basal con-
ditions – without DSS-colitis – inhibition or deletion of MPO ac-
tivity favors colon tumor occurrence, suggesting that ApcMin/þ
mice may rely on basal MPO activity for mucosal host defense
against tumors [36]. The occurrence of colon tumors that coin-
cided with inhibition of basal MPO activity may relate to the dis-
position of H2O2, its substrate. Ordinarily, consumption of H2O2 by
MPO may help restrain peroxide ‘tone’ below the level needed for
optimal COX activity [37]. Accordingly, inhibition or deletion of
MPO activity in non-inﬂamed bowels may allow H2O2 to accu-
mulate and reach levels supporting COX-mediated or
H2O2-mediated colon tumor progression [38]. Fig. 5 depicts a
speculative model to explain the apparent dichotomy between
tumor occurrence and inhibition of MPO activity in inﬂamed ver-
sus non-inﬂamed colons. A similar dichotomy exists in humans.
On one hand, MPO protein levels correlate directly with colorectal
cancer progression [21], and colon tumors have elevated MPO
activity compared to non-inﬂamed colonic mucosa [39,40]. On the
other hand, malignancies have been associated with human MPO
deﬁciency and MPO deﬁcient neutrophils fail to destroy malignant
cells [41,42].
Resorcinol causes irreversible, H2O2-dependent loss of perox-
idase activity in various heme-containing peroxidases [43], in-
cluding both MPO and EPO. Strictly speaking, we cannot exclude a
contribution from other granulocytes, such as eosinophils, in DSS-
induced colitis in ApcMinþ mice. A role for eosinophil peroxidase
(EPO) in DSS- induced colitis has been established using EPO
‘knockout' mice (EPO /) [23]. Environmental and genetic varia-
tion can modify mouse models of disease [44–47], consequently
results with (EPO/) mice on a 129/Ola/Hsd129/SvJ back-
ground, do not extrapolate seamlessly to ApcMin/þ mice on a
C57Bl/6J background. Generally, the involvement of neutrophils in
DSS colitis in C57/Bl6J mice including ApcMin/þ mice is well es-
tablished [3–7]. It should be stressed that the investigators
studying the role of eosinophils in DSS colitis were, themselves,
unable to exclude a contribution from neutrophils [23].
Consistent with gut's dual role as a digestive organ and a
lymphoid organ, diet and inﬂammation can modify colon cancer
risk in complex ways. To interpret these complexities Bruce et al.
[34] have proposed an intriguing model that integrates two se-
parate mechanisms: (1) disruption of cellular energetic signaling
processes, leading to growth and proliferation; (2) focal loss of
Fig. 5. Legend. Hypothetical model of the relationship between MPO activity and colon tumor occurrence in inﬂamed colon (left) and non-inﬂamed colon (right).
M. Al-Salihi et al. / Redox Biology 6 (2015) 218–225224epithelial barriers, inﬂammation and oxidative stress, leading to
proliferation and mutation. Our results lend support and reﬁne-
ment to this model. In evaluating cancer risk Swenberg et al. [48]
and Wild [49] have championed a comprehensive approach which
considers all exposure events – both exogenous and endogenous.
This includes electrophilic molecules that are generated in living
cells and organs through normal physiology, lifestyle, and nutri-
tion. Our results suggest that MPO is an aspect of the ‘exposome’
[49] that deserves attention in the etiology and control of color-
ectal cancer [50–52].Animal experiments
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